chronic%20obstructive%20pulmonary%20disease
CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Chronic obstructive pulmonary disease (COPD) is an inflammatory respiratory disease characterized by reversible airflow limitation.

The patient usually have chronic cough, sputum production or dyspnea with or without history of risk factors for the disease.

The chronic airflow limitation is caused by a combination of small airways disease and parenchymal destruction.

It is a preventable & treatable disease.

Patient Education

  • It plays an important role in the following:
  • Increasing patient’s knowledge & understanding of the disease
  • Improving skills in symptom recognition, breathing & physical exercise, medication use including proper technique & environmental modification
    • Important to note that adherence to inhaled medications has been associated with reduced risk of death & hospital admission due to COPD exacerbations
    • Measures must be taken to reduce total personal exposure to tobacco smoke, occupational dusts & chemicals & air pollutants
  • Improving attitude toward nutrition & exercise, smoking cessation, quality of life factors & coping skills (eg relaxation techniques, stress management)
  • Improving patient responses to exacerbations
  • Initiating discussions about end-of-life issues including advance directives

Lifestyle Modification

Smoking Cessation

  • The single most effective & cost effective method to reduce the risk of developing COPD & to stop its progression
    • Counseling may be employed to aid patient
    • Pharmacotherapies to aid smoking cessation eg Nicotine preparations, Bupropion & Nortriptyline may be considered (See Smoking Cessation Disease Management Chart)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Jun 2017
The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.
Jairia Dela Cruz, 21 Jun 2017
Control treatment with montelukast may effectively reduce acute exacerbations in preschool children with mild persistent asthma, according to a study from Japan.
Tristan Manalac, 27 Jun 2017
Prolonged sleep duration is an independent predictor of higher incident atrial fibrillation (AF) risks in a Chinese population, reports a new prospective, population-based study.
Rachel Soon, 01 Jun 2017

Pirfenidone, an oral antifibrotic and anti-inflammatory agent, is now indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in Malaysia.